SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 376 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Ms. Laura Francis es el Chief Executive Officer de SI-BONE Inc, se unió a la empresa desde 2015.
¿Qué tal es el rendimiento del precio de la acción SIBN?
El precio actual de SIBN es de $12.57, ha azalmış un 3.23% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de SI-BONE Inc?
SI-BONE Inc pertenece a la industria Health Care y el sector es Health Care
¿Cuál es la capitalización bursátil de SI-BONE Inc?
La capitalización bursátil actual de SI-BONE Inc es $555.2M
¿Es SI-BONE Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 12 analistas han realizado calificaciones de análisis para SI-BONE Inc, incluyendo 4 fuerte compra, 10 compra, 1 mantener, 0 venta, y 4 fuerte venta